期刊文献+

胺碘酮预防心房颤动复发的疗效及不良反应分析 被引量:1

下载PDF
导出
摘要 目的探讨胺碘酮在持续性心房颤动复律后维持窦性心律方面的作用和不良反应,同时观察心房颤动复发的影响因素。方法对63例初诊为持续性心房颤动的患者,经药物或电复律后给予胺碘酮2周的负荷量,以后0.2g每日1次维持,随访18个月,观察心房颤动复发情况及药物相关的不良反应、治疗前后左心房功能的变化,并定期行心电图、血常规、肝、肾功能和胸部X射线、甲状腺功能及眼科方面的检查。结果有12例病人出现心房颤动复发,59%发生在前3个月内,维持治疗1年后较少出现心房颤动复发。复发者的左心房内径在观察期前后均大于未复发者(P<0.05)。胺碘酮长期维持治疗未发现严重毒性反应、副作用。结论胺碘酮对持续性心房颤动复律后的维持治疗有一定的作用,长期低剂量维持相对安全。心房颤动的复发与左心房功能有一定的关系。
作者 韦汐
出处 《右江民族医学院学报》 2006年第6期946-947,共2页 Journal of Youjiang Medical University for Nationalities
  • 相关文献

参考文献9

  • 1Wijffels MC,Kirchhof CJ,Dorland R,et al.AF begets AF:a study in awake chronically instrumented goats[J].Circulation,1995,92(7):1954-1968.
  • 2Ravelli F,Allessie MA.The effects of atrial dilatation on refractory period and vulnerability to atrial fibrillation in the isolated Lagendorff-perfused rabbit heart[J].Circulation,1997,96(5):1686-1695.
  • 3Goldschlager N,Epstein AE,Naccarelli G,et al.Practical guidelines for clinicians who treat patients with amiod-arone.Practice Guidelines Subcommittee,North American Soc-iety of Pacing and Electrophysiology[J].Arch Intern Med,2000,160(12):1741-1748.
  • 4郭林妮,黄元铸,蒋文平,李庚山,陆再英,戚文航,任自文,吴宁,向晋涛,朱俊,方圻,高润霖.胺碘酮抗心律失常治疗应用指南[J].中国心脏起搏与心电生理杂志,2004,18(6):401-407. 被引量:392
  • 5耿现仓,司海芹.心房颤动患者血栓栓塞的防治[J].新医学,2002,33(6):378-379. 被引量:6
  • 6Podrid PJ.Amiodarone:reevaluation of an old drug[J].Ann Intem Med,1995,12(2):698-700.
  • 7Allessie MA.Atrial electrophysiological remodeling:another vicious circle[J].J Cardiovasc Electrophysiol,1998,9(12):1378-1393.
  • 8李建平,张薇,黎莉,杨贵荣,苗雅,张运.贝那普利联用胺碘酮预防心房颤动复发改善左心房功能临床研究[J].新医学,2004,35(11):669-671. 被引量:5
  • 9Ogunyankin KO,Singh BN.Mortality reduction by antiadrenergic modulation of arrhythmogenic substrate:significance of combining beta blockers ang amiodarone[J].Am J Cardiol,1999,84(9A):76R-82R.

二级参考文献15

  • 1[1]Allessie MA. Atrial electrophysiological remodeling: another vicious circle? J Cardiovasc Electrophysiol, 1998, 9 (12): 1378-1393.
  • 2[2]Wijffels MCEF, Kirchhof CJHJ, Dorland R, et al. AF begets AF: a study in awake chronically instrumented goats. Circulation, 1995, 92 ( 7 ): 1954-1968.
  • 3[3]Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age, distribution and gender of patients with atrial fibrillation. Arch Intern Med, 1995, 155 (5): 469-473.
  • 4[5]Nakashima H, Kumagai K, Urata H, et al. Angiotensin Ⅱ antagonist prevents electrical remodeling in atrial fibrillation. Circulation, 2000, 101 (22): 2612-2617.
  • 5[6]Pedersen OD, Bagger H, Kober L, et al. Trandolapril reduces the inci dence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation, 1999, 100 (4): 376-380.
  • 6[7]Ravelli F, Allessie MA. The effects of atrial dialatation on refractory period and vulnerability to atrial fibrillation in the isolated Lagendorff-perfused rabbit heart. Circulation, 1997, 96 (5): 1686-1695.
  • 7Antman EM, Anbe DT, Armstrong PW,et al.ACC/AHA guidlines for the management of patients with ST-elevation myocardial infarction-executive summary[J]. Circulation,2004,110:588
  • 8Hammill SC.Cardiac arrhythmias[J].JACC,2004,44(suppl 2):16A
  • 9Goldschlager N, Epstein AE, Naccarelli G, et al. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology[J]. Arch Intern Med,2000,160:1 741
  • 10The American Heart Association in Collaboration with the International Liais on Committee on Resuscitation. Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 6: Advance cardiovascular life support. Section 5: Phamacology I: Agents for Arrhythmias[J]. Circulation, 2000, 102(Suppl 8): I 112

共引文献400

同被引文献4

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部